Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1956
|
| gptkbp:ATCCode |
N05AB04
|
| gptkbp:availableOn |
gptkb:tablet
injectable suppository |
| gptkbp:brandNameFor |
prochlorperazine
|
| gptkbp:chemicalClass |
phenothiazine
|
| gptkbp:contraindication |
children under 2 years
hypersensitivity to phenothiazines |
| gptkbp:eliminationHalfLife |
4-8 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Compazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
dopamine receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intramuscular rectal |
| gptkbp:sideEffect |
constipation
dizziness blurred vision drowsiness dry mouth extrapyramidal symptoms |
| gptkbp:usedFor |
nausea
schizophrenia vomiting anxiety |
| gptkbp:bfsParent |
gptkb:Prochlorperazine
|
| gptkbp:bfsLayer |
7
|